Trials / Unknown
UnknownNCT03650933
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G-CHOP | 6 cycles(each cycle is 3 weeks) |
| BIOLOGICAL | R-CHOP | 6 cycles(each cycle is 3 weeks) |
Timeline
- Start date
- 2018-12-28
- Primary completion
- 2022-08-17
- Completion
- 2025-12-31
- First posted
- 2018-08-29
- Last updated
- 2024-02-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03650933. Inclusion in this directory is not an endorsement.